Investment Management Corp of Ontario Has $809,000 Stock Holdings in Insulet Co. (NASDAQ:PODD)

Investment Management Corp of Ontario increased its position in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 36.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,099 shares of the medical instruments supplier's stock after purchasing an additional 828 shares during the period. Investment Management Corp of Ontario's holdings in Insulet were worth $809,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. grew its stake in shares of Insulet by 4.0% in the 3rd quarter. Principal Financial Group Inc. now owns 86,210 shares of the medical instruments supplier's stock worth $20,065,000 after purchasing an additional 3,355 shares during the last quarter. Graypoint LLC grew its position in Insulet by 5.3% in the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier's stock worth $243,000 after buying an additional 47 shares during the last quarter. Czech National Bank increased its holdings in shares of Insulet by 6.5% in the fourth quarter. Czech National Bank now owns 15,209 shares of the medical instruments supplier's stock valued at $3,971,000 after buying an additional 926 shares in the last quarter. CHICAGO TRUST Co NA bought a new stake in shares of Insulet during the 4th quarter worth $294,000. Finally, Cooper Financial Group boosted its stake in shares of Insulet by 14.2% during the 4th quarter. Cooper Financial Group now owns 1,021 shares of the medical instruments supplier's stock worth $267,000 after acquiring an additional 127 shares in the last quarter.

Analysts Set New Price Targets

PODD has been the subject of a number of recent analyst reports. Barclays lifted their price objective on shares of Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. Wells Fargo & Company set a $322.00 price target on Insulet in a report on Monday, April 28th. Oppenheimer increased their price objective on Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Raymond James reaffirmed an "outperform" rating and set a $328.00 target price (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Finally, Canaccord Genuity Group upped their target price on Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Insulet presently has a consensus rating of "Moderate Buy" and a consensus price target of $306.53.

Insider Transactions at Insulet

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the transaction, the senior vice president now owns 23,180 shares of the company's stock, valued at approximately $7,382,134.60. This represents a 18.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the company's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now directly owns 3,231 shares in the company, valued at $888,525. This trade represents a 36.10% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Insulet Stock Performance

Insulet stock traded up $2.73 during trading hours on Friday, reaching $324.75. 836,387 shares of the company were exchanged, compared to its average volume of 708,259. The firm has a market cap of $22.85 billion, a price-to-earnings ratio of 56.09, a PEG ratio of 3.62 and a beta of 1.26. Insulet Co. has a 12 month low of $170.67 and a 12 month high of $326.10. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a 50-day moving average of $262.55 and a 200 day moving average of $265.81.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. During the same period in the prior year, the company posted $0.73 earnings per share. Insulet's revenue was up 28.8% on a year-over-year basis. As a group, research analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.